This site is intended only for healthcare professionals resident in India

Search

Menu

Close

Sign InLog Out
Our medicinesTherapy areasExplore ContentExplore contentMaterialsVideosLet's connectLet's ConnectPfizer medical information

Menu

Close

AboutAboutHeritageMechanism Of ActionPatient ProfilesStable SHL PatientsPatient on the MovePatients Currently Taking an EHLPatient Actively Involved in SportAboutPurification ProcessDosingRecommended Dosing SchedulesProphylaxisOn-demandAdministrationDose AdministrationEfficacy and SafetyEfficacy and SafetyClinical EfficacySafety ProfileMonitoringPatient Reported OutcomesReal-world dataSupport & ServicesSupport & ServicesPrescribing InformationMaterialsVideosLatest ArticlesEvents
DosingRecommended dose modificationsDose Administration

Patients on the Move

Considerations for choosing an appropriate factor product

  

More frequent dosing may provide higher factor levels1

  

Depending on patients' needs and lifestyles, continuing with or switching to an SHL factor product may represent an appropriate option.1
 

Higher factor levels and more frequent peaks may be needed for some patients.1

  • The importance of peak and trough levels in hemophilia patients is still not clearly understood. However, studies suggest that higher trough levels and greater area under the  curve may correlate to fewer bleeds, especially in the joints2
     

  • In patients with more sedentary lifestyles, longer dose intervals may be acceptable1
     
  • In patients with a less than below average half-life prolongation, target joints* or more on-the move lifestyles, higher and more frequent peak factor levels may be beneficial for sufficient bleed protection1,3
BeneFIX® offers the flexibility to infuse on-demand or prophylactically based on your patients' needs.4    Mahesh – a patient on the move  Patient profiles are hypothetical and for discussion purposes only.Who is Mahesh?

On-the-move adult
 

A 36-year-old patient with severe
hemophilia B. A university administrator who travels often and loves playing outdoors with his children.

  

Treatment

  

Mahesh is currently on prophylaxis with BeneFIX® at a dose of 40 IU/kg every 3 to 4 days. He has experienced occasional joint pain and expects the dosing to be flexible and to consistently protect his joints.
He wants to consult his haematologist about increasing his dose as he is keen to avoid joint bleeds.

  


These patients may be doing everyday activities such as commuting to work, playing with their children or going for a walk. Patients who plan to engage in certain physical activities may benefit from higher levels and more frequent peaks.1

Why BeneFIX® may be appropriate for patients like Mahesh

  

Efficacy that is established
for prophylaxis, on-demand and surgery5,7,8
Convenient storage options
storage flexibility through room temperature storage (2 - 30 °C).4 Do not freeze4
Flexible dosing
with a predictable PK to support your patient's everyday life10
Favourable safety
with low inhibitor formation6
A broad range of vial sizes
(250, 500, 1000, 2000, 3000 IU) so you can individualise FIX coverage for your patients4

  

Informed decisions may lead to more favourable outcomes.1,3

To help ensure that patients are actively involved in creating their treatment plan, consider discussing the following points to help determine if an SHL or an EHL is more appropriate:
 

  • Lifestyle and activity level
  • Bleed pattern
  • Joint health
  • PK profile

  

*A target joint is a joint in which 3 or more spontaneous bleeds occurred within a consecutive 6-month period.9

  

EHL, extended half-life; FIX, factor IX; PK, pharmacokinetics; SHL, standard half-life.

  

References:

Collins P, Chalmers E, Chowdary P, et al. The use of enhanced half-life coagulation factor concentrates in routine clinical practice: guidance from UKHCDO. Haemophilia. 2016;22(4):487-498.Dunn A. The long and short of it: using the new factor products. Hematology Am Soc Hematol Educ Program. 2015;2015:26-32.Nossair F, Thornburg CD. The role of patient and healthcare professionals in the era of new hemophilia treatments in developed and developing countries. Ther Adv Hematol. 2018;9(8):239-249.BeneFIX. Local prescribing document. Pfizer India. LPDBEN092021.Roth DA, Kessler CM, Pasi KJ, et al. Human recombinant factor IX: safety and efficacy studies in hemophilia B patients previously treated with plasma-derived factor IX concentrates. Blood. 2001;98(13):3600-3606. Rendo P, Smith L, Lee HY, Shafer F. Nonacog alfa: an analysis of safety data from six prospective clinical studies in different patient populations with haemophilia B treated with different therapeutic modalities. Blood Coagul Fibrinolysis. 2015;26(8):912-918.Shapiro AD, Di Paola J, Cohen A, et al. The safety and efficacy of recombinant human blood coagulation factor IX in previously untreated patients with severe or moderately severe hemophilia B. Blood. 2005;105(2):518-525.Ragni MV, Pasi KJ, White GC, et al. Use of recombinant factor IX in subjects with haemophilia B undergoing surgery. Haemophilia. 2002;8(2):91-97.Srivastava A, Santagostino E, Dougall A, et al. WFH guidelines for the management of hemophilia, 3rd edition. Haemophilia. 2020;26(suppl 6):1-158.Korth-Bradley JM, Rendo P, Smith L, Altisent C. Pharmacokinetics, efficacy, and safety of nonacog alfa in previously treated patients with moderately severe to severe haemophilia B. Clin Ther. 2016;38(4):936-944.


PP-BEN-IND-0025 22/07/22

Patient Profiles


Dosing

BeneFIX® provides dosing options based on individual needs

Learn more


Efficacy and Safety

Proven efficacy and protection across dosing regimen

Review efficacy profile


Real-world Data

See how BeneFIX® performs in real-life settings.

Review real-world data
PfizerPro AccountPfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign in or RegisterSign inRegisterAccountSign Out
 
These pages are not intended for patients or for members of the general public. The web pages contain promotional content. For the use only of Registered Medical Practitioners or a Hospital or a Laboratory. Full prescribing information available on request. For more details on, Who is a Registered Medical Practitioner, please visit "https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf", Page No. 39, Rule 2 part (ee), last accessed on 26th April2021.
​​​​​​​
Address: The Capital,  A Wing, 1802, 18th Floor, Plot No. C-70, ‘G’ Block, Bandra Kurla Complex, Bandra East, Mumbai – 400051, India.
 
PP-BEN-IND-0025

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

Heading

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

ButtonButton

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Hac habitasse platea dictumst quisque sagittis purus sit amet volutpat. Lectus magna fringilla urna porttitor rhoncus. Venenatis urna cursus eget nunc scelerisque viverra. Id donec ultrices tincidunt arcu non sodales.

Sagittis aliquam malesuada bibendum arcu vitae elementum curabitur. Pellentesque elit ullamcorper dignissim cras tincidunt. Orci ac auctor augue mauris augue neque. Dui vivamus arcu felis bibendum ut tristique et egestas quis. Sed vulputate mi sit amet mauris commodo.

Nunc eget lorem dolor sed viverra ipsum. Sed ullamcorper morbi tincidunt ornare.

Copyright © 2023 Pfizer Limited, India. All rights reserved. Applicable for Pfizer Products, Product Microsites and Therapy Areas section of the website:
  • All content published herein is intended and strictly only for informational, educational, academic and/or research purposes and shall not be utilized to diagnose or treat a health problem or disease without referring to the full prescribing information for list of approved indications as contained in the product package insert
  • While due care and caution has been taken to ensure that the content herein is free from mistakes or omissions, Pfizer makes no claims, promises or guarantees about the accuracy, completeness or adequacy of the information herein
For the use only of Registered medical practitioners* or a Hospital or a Laboratory

These pages are not intended for patients or for members of the general public. The web pages contain promotional content.

 

If you select 'No', you will be redirected to Pfizer.co.in

For more details on, Who is a Registered medical practitioner*, please visit https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf , Page No. 39, Rule 2 part (ee), last accessed on 26th April 2021.
Address: The Capital, A Wing, 1802, 18th Floor, Plot No. C-70, 'G' Block, Bandra Kurla Complex, Bandra East, Mumbai - 400051.


PP-DOL-IND-0251 18 JAN 2023Yes No
You are now leaving PfizerPro website
​
​​​​​You are now leaving Pfizer Pro website and will be redirected to another website. Note that you will be governed by the Terms & Conditions and Privacy Policy of the external website. Would you like to continue?
PP-DOL-IND-0251 18 JAN 2023